“We are extremely pleased to welcome David to the Histogenics’ Board of Directors,” said Adam Gridley, president and CEO of Histogenics. “David’s financial and industry expertise and experience make him an excellent choice for Histogenics as both a board member and Chairman of the Audit Committee.”
Mr. Gill joined EndoChoice as CFO in 2014. He has held the CFO position with a number of other organizations including INC Research and TransEnterix.
Histogenics focuses on regenerative medicine in the musculoskeletal marketplace.
More articles on gastroenterology:
5 must-reads for independent GI practices
8 gastroenterologist inventors
pCLE effective at diagnosing biliary cancer patients during ERCP, study says
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.